Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
FY2025 · 10-K disclosure
689 daily bars · split adjusted
Current price $60.11
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 13, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 14, 26 | Greenwell Scott A. | officer: President, PharMerica | M-Exempt | 11,973 @ $22.27 | $266.6K |
Daily · Wilder smoothing
| BTIG |
| maintain |
| Buy |
| Buy |
| Aug 3, 26 | BTIG | maintain | Buy | Buy |
| Jul 14, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 14, 26 | Keybanc | maintain | Overweight | Overweight |
| Jul 13, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 8, 26 | UBS | maintain | Buy | Buy |
| Jul 2, 26 | B of A Securities | maintain | Buy | Buy |
| Jun 22, 26 | BTIG | maintain | Buy | Buy |
| Jun 18, 26 | TD Cowen | maintain | Buy | Buy |
| Sep 14, 26 |
| Greenwell Scott A. |
| officer: President, PharMerica |
| S-Sale |
| 15,099 @ $57.91 |
| $874.4K |
| Sep 14, 26 | Greenwell Scott A. | officer: President, PharMerica | M-Exempt | 11,973 @ $22.27 | $266.6K |
| Jul 25, 26 | Rousseau Jon B | director, officer: See Remarks | F-InKind | 56,319 @ $72.91 | $4.11M |
| Jun 20, 26 | Greenwell Scott A. | officer: President, PharMerica | F-InKind | 2,487 @ $66.25 | $164.8K |
| Jun 11, 26 | Shah Nigam H. | director | A-Award | 4,013 | — |
| Jun 11, 26 | Shah Nigam H. | 0 | — |
| Jun 5, 26 | Kkr Group Partnership L.P. | 10 percent owner | S-Sale | 14,669,771 @ $58.45 | $857.5M |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.56 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 27.14 | Oscillator | Neutral |
| Williams %R (14) | -94.21 | Oscillator | Buy |
| MACD (12, 26, 9) | 0.50 (Hist -0.18) | Oscillator | Sell |
| Average Directional Index (14) | 18.17 (+DI 21.7 / -DI 25.8) | Trend | Neutral |
| EMA 20 | 61.13 | MA | Sell |
| SMA 20 | 61.14 | MA | Sell |
| EMA 50 | 60.87 | MA | Sell |
| SMA 50 | 59.87 | MA | Buy |
| SMA 200 | 54.13 | MA | Strong Buy |
Stock news · updated daily
Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of BrightSpring Health Services, Inc. (NASDAQ: BTSG) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,630 shares of the company's stock, valued at approximately $1,738,000. Several
State of Alaska Department of Revenue cut its stake in BrightSpring Health Services, Inc. (NASDAQ: BTSG) by 60.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,826 shares of the company's stock after selling 38,367 shares during the quarter. State of Alaska
BrightSpring's shares surge 67.3% year to date, fueled by strong pharmacy and provider growth, improving profitability and a brighter 2026 outlook.
I believe BrightSpring Health Services' pharmacy and home-care businesses have a few ways to monetize their sizeable revenues into higher EBITDA over time. BTSG's new oncology distribution wins also grow their addressable market, which is why drug adoption is vital going forward. BTSG's recently acquired home-health branches also have interesting potential as their integration progresses.
Healthcare offers investors a potential combination of offense with forward earnings and defense with rising demand amid persistent macro-economic uncertainty. The healthcare sector is positioned for above-average long-term growth, supported by aging demographics, rising medical demand, and increased spending that's expected to outpace the broader economy. Strong forward revenue, EBITDA, and earnings growth demonstrate how select healthcare services and facilities companies can significantly outperform their sector peers.
LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on Friday, October 30, 2026, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day.
BrightSpring Health Services is expanding AI and automation across its operations, with early margin gains and more benefits expected later in 2026 and 2027.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 31, 2026 | 0.40 | 0.45 | Beat 13.6% | $3.87B |
| May 1, 2026 | 0.29 | 0.39 | Beat 34.5% | $3.61B |
| Feb 27, 2026 | 0.34 | 0.33 | Miss -2.9% | $3.55B |
| Oct 31, 2025 | 0.26 | 0.30 | Beat 13.9% | $3.33B |
| Aug 1, 2025 | 0.19 | 0.22 | Beat 15.8% | $3.15B |
| May 2, 2025 | 0.08 | 0.19 | Beat 137.5% | $2.88B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 16, 2026 | 2026-09-16 16:04:26 | View |
| SC 13G/A | Aug 6, 2026 | 2026-08-06 10:17:34 | View |
| SC 13G | Jul 31, 2026 | 2026-07-31 11:24:27 | View |
| 10-Q | Jul 31, 2026 | 2026-07-31 08:45:47 | View |
| 8-K | Jul 31, 2026 | 2026-07-31 06:05:14 | View |
| 4 | Jul 28, 2026 | 2026-07-28 20:31:00 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| 4 | Jun 22, 2026 | 2026-06-22 16:05:13 | View |
| 4 | Jun 12, 2026 | 2026-06-12 18:32:35 | View |
| 3 | Jun 12, 2026 | 2026-06-12 18:31:19 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BTSG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 42.0x | -30.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 33.0x | EPS est. 1.82 | Discount |
| Price / Book | 6.0x | 2.8x | Elevated |
| Price / Sales | 0.8x | 0.3x | Elevated |
| EV / EBITDA | 21.5x | 16.1x | Elevated |
| Return on equity | 15.2% | — | Healthy |
| Gross margin | 12.4% | 15.7% | Below hist. |
| Debt / Equity | 1.17 | 3.84 | Moderate |
| Piotroski / Altman Z | 7/9 | Z 4.67 | Safe zone |
Discounted cash flow model